The treatment of soft tissue sarcomas (STSs), which encompass a group of more than 70 histologically and biologically distinct subtypes of cancer, is emblematic of an orphan disease.1 About 13 000 patients are diagnosed as having STS in the United States every year,2 survival rates are poor and have not changed in the last 40 years, and there is little funding to support scientific discovery of disease biology to improve treatment regimens. Clinical presentation and prognosis are influenced not only by the extent of disease and histological subtypes, but by tumor location as well. There is a significant unmet need for improved systemic therapies in the treatment of patients with STS.
Roland CL, Wong SL. Treatment for Advanced Soft Tissue Sarcoma: An Informative Neutral Trial. JAMA. 2020;323(13):1251–1252. doi:10.1001/jama.2020.0567
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: